| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | C/O ANAPTYSBIO, INC., 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO | /s/ Eric Loumeau | 08 Jan 2026 | 0001239648 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANAB | Common Stock | Options Exercise | +5,545 | +42% | 18,796 | 06 Jan 2026 | Direct | F1 | ||
| transaction | ANAB | Common Stock | Sale | $90,987 | -2,017 | -11% | $45.11 | 16,779 | 07 Jan 2026 | Direct | F2 |
| transaction | ANAB | Common Stock | Sale | $239,672 | -5,281 | -31% | $45.38 | 11,498 | 07 Jan 2026 | Direct | F3, F4 |
| transaction | ANAB | Common Stock | Sale | $84,926 | -1,841 | -16% | $46.13 | 9,657 | 07 Jan 2026 | Direct | F3, F5 |
| transaction | ANAB | Common Stock | Sale | $23,615 | -500 | -5.2% | $47.23 | 9,157 | 07 Jan 2026 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANAB | Restricted Stock Unit | Options Exercise | $0 | -5,545 | -50% | $0.000000 | 5,545 | 06 Jan 2026 | Common Stock | 5,545 | Direct | F1, F6 | |
| transaction | ANAB | Restricted Stock Unit | Award | $0 | +17,100 | $0.000000 | 17,100 | 06 Jan 2026 | Common Stock | 17,100 | Direct | F1, F7 | ||
| transaction | ANAB | Stock Option (right to buy) | Award | $0 | +23,200 | $0.000000 | 23,200 | 06 Jan 2026 | Common Stock | 23,200 | $43.91 | Direct | F8 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| F2 | The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| F3 | The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. |
| F4 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.835 per share, inclusive. The reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.96 to $46.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| F7 | The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| F8 | The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |